17 Capital Partners’s Idexx Laboratories IDXX Stock Holding History

17 Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513K	Sell	975 -100	-9%	-$56.1K	0.23%	127
2026 Q1	$604K	Sell	1,075 -390	-27%	-$250K	0.31%	106
2025 Q4	$991K	Sell	1,465 -8	-0.5%	-$5.45K	0.51%	67
2025 Q3	$941K	Buy	1,473 +328	+29%	+$199K	0.51%	69
2025 Q2	$614K	Buy	1,145 +15	+1%	+$7.17K	0.35%	90
2025 Q1	$475K	Buy	+1,130	New	+$491K	0.3%	98
2024 Q4	–	Sell	-720	Closed	-$364K	–	139
2024 Q3	$364K	Sell	720 -38	-5%	-$18.5K	0.24%	112
2024 Q2	$369K	Buy	758 +10	+1%	+$5.02K	0.26%	98
2024 Q1	$404K	Hold	748	–	–	0.3%	85
2023 Q4	$415K	Buy	+748	New	+$351K	0.38%	71
2022 Q3	$276K	Hold	848	–	–	0.38%	71
2022 Q2	$297K	Sell	848 -810	-49%	-$330K	0.38%	76
2022 Q1	$907K	Buy	1,658 +1,028	+163%	+$541K	0.95%	44
2021 Q4	$415K	Hold	630	–	–	0.38%	73
2021 Q3	$392K	Sell	630 -800	-56%	-$538K	0.37%	78
2021 Q2	$903K	Buy	+1,430	New	+$790K	0.84%	46

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

17 Capital Partners's IDXX Position: Q2 2026 in Review

17 Capital Partners reduced its Idexx Laboratories (IDXX) stake by 9.3% in Q2 2026, selling an estimated $56.1K and leaving 975 shares worth $513K. The position accounts for 0.23% of the portfolio, ranked #127.

17 Capital Partners first reported a position in IDXX in Q2 2021 and has held it in 16 quarters since. The position peaked at $991K in Q4 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

17 Capital Partners held 975 shares of Idexx Laboratories worth $513K as of Q2 2026.
17 Capital Partners sold 100 Idexx Laboratories shares in Q2 2026, an estimated $56.1K.
Idexx Laboratories made up 0.23% of 17 Capital Partners's portfolio in Q2 2026, its #127 holding.
17 Capital Partners first reported a position in Idexx Laboratories in Q2 2021 and has held it in 16 quarters since.
17 Capital Partners's Idexx Laboratories position peaked at $991K in Q4 2025.
1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.